NEW CE APPROVALS: Addiction, OCD and Comorbid Anxiety

New CE approvals expand the treatment options of MagVenture TMS Therapy® 

Sidebox Sack Galimberty

MagVenture has received CE approval for noninvasive brain treatment of Addiction and Obsessive-Compulsive Disorder( OCD).  In addition, MagVenture TMS Therapy® can reduce the symptoms of Comorbid Anxiety in patients suffering from depression. MagVenture was CE approved for Major Depressive Disorder (MDD) in 2011.

“These new CE approvals are based on the dedicated clinical TMS research studies conducted at multiple renowned research institutions,” states Senior Scientist Claus Mathiesen, PhD, MagVenture A/S, further adding: “We believe the CE approvals have the potential of becoming a true game changer for the clinical application of TMS therapy  and we cannot wait to bring these new treatment options to the market with the potential to provide help for millions of people affected by these disorders." 


Watch this short video about the new CE approvals


Research results

For Addiction, a pilot study conducted by an Italian research team led by Professor Luigi Gallimberti and Antonelli Bonci at Novella Fronda Foundation demonstrated a 69% effect for the TMS group and 19% for the control group receiving the standard of care treatment (Terraneo et al. 2016.). These initial findings were followed up by an observational study (Madeo et al. 2020.)

“Our study involved 284 individuals with cocaine addiction. After receiving TMS therapy, they were followed for two years and eight months and our results clearly showed that TMS therapy led to long-lasting reductions in cocaine use,” explains neurologist Graziella Madeo, who was also part of the research team:  “TMS can change the abnormal behavior by targeting the underlying brain-circuit dysfunction induced by substance use. Not only craving is reduced or absent, but our patients also experience changes in other aspects of their life, including a greater control in conditions potentially triggering a relapse in cocaine use.”

For OCD, a 45% response rate was reported for the group receiving treatment, compared to 18% in the sham group (Carmi et al. 2018). For depression, the world’s largest randomized controlled study in TMS to date – comprising 414 patients – showed a response rate of 49% and a remission rate of 32% for those receiving theta burst magnetic stimulation (Blumberger et al. 2018). In addition, with this newly approved clinical benefit, TMS has also proven effective in treating the symptoms of anxiety in patients with depression with a response rate of 39% and remission rate of 23%, respectively (Clarke et al. 2019)

Webinar: Introduction to TMS for addiction 

On September 7, 2021, Magventure hosted a webinar under the title: "Introduction to TMS for Psychoactive Substance Use Disorder. "  The webinar is intented for health care professionals in the European Union. To watch a recording of the webinar, please click here

Why choose MagVenture TMS Therapy®

MagVenture offers solutions ranging from the simplest systems to high-performance setups tailored for high patient throughput and upgradable for possible future indications. Your previous TMS experience, expected patient volume, and budget will also be taken into account.  Highlights of the system include:

  • Well-proven
  • Outpatient procedure
  • Non-invasive
  • Optimised patient comfort
  • Most common side effects: headache and nausea

Are you interested in more information?

Please download flyers for Addiction, OCD, and Comorbid Anxiety or read the full press release. Please do not hesitate to contact us if you want to know more about how you can get MagVenture TMS Therapy® in your clinic. Our team of experts will be happy to help.

CE Approvals and clinical benefits

MagVenture TMS Therapy® – CE approvals
“Treatment of psychoactive substance use disorder (PSUD) in adult patients.”

“As an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).”

“Treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode.”

MagVenture TMS Therapy® – clinical benefit
For subjects responding to the treatment of MDD, who have symptoms of comorbid anxiety, the clinical benefit can additionally include an improvement of anxiety symptoms.

Additional Info

  • news-gallery-image: news-gallery-image

contact us

Talk to an expert

Do you need help? Let us know how our experts can help you.

Subscribe to the MagVenture Newsletter

By clicking on the submit button, I confirm that I have read and agree to MagVenture’s Terms of Use.